胶囊内镜对小肠腔内隆起性病变诊断价值

目的探讨胶囊内镜对小肠腔内隆起性病变的诊断价值。方法计算小肠腔内隆起性病变的例数,描述隆起性病变的特点和分析影响因素,初步判断隆起性病变的性质。结果共发现45处隆起,其中22处证实为隆起性病变,约占隆起总数的48.9%,阴性排除率51.1%;胶囊内镜对体积小的隆起性病变观察清晰,体积、位置和小肠液等因素影响观察效果。结论胶囊内镜对隆起性病变具有较高的指导诊断价值。     

养精胶囊通过LncRNA H19调控StAR促进睾酮合成的实验研究※

目的 研究养精胶囊对LncRNA H19调控StAR作用及促进睾酮合成机制。方法 以体外MLTC-1细胞培养为模型，分别加入2 mL的培养基以及终浓度为0.01 mg/mL、0.1 mg/mL、1 mg/mL的养精胶囊水提物，并将其分别作为对照组和养精胶囊低、中、高剂量组，作用24 h。通过ELISA测定细胞T和FT浓度，通过qRT-PCR、Western Blot分别检测养精胶囊对MLTC-1中LncRNA H19 mRNA、StAR mRNA以及StAR蛋白表达的影响。结果 养精胶囊水提物可以显著提高MLTC-1细胞上清T和FT浓度浓度，同时还可以明显促进LncRNA H19 mRNA以及StAR mRNA和蛋白的表达水平，与对照组比较有统计学差异（P<0.05）。结论 养精胶囊可以通过LncRNA H19调控StAR，进而增加睾酮合成。     

海珠益肝胶囊对小鼠免疫性肝损伤的影响

目的:进一步证实海珠益肝胶囊对肝损伤小鼠的保肝降酶作用。方法:来用卡介苗 脂多糖(BCG LPS)造成免疫性肝损伤模型小鼠,观察本品对血清中ALT、AST活力单位、肝脾脏器系数和肝脏病理组织学损伤程度的影响。结果:药物能降低血清中ALT、AST活力单位(P<0.01);减小肝脾肿大及脏器系数(P<0.01);减轻肝组织病理损伤程度。结论:海珠益肝胶囊对BCG LPS所致肝损伤小鼠有明显保肝降酶作用。     

超高效液相色谱－蒸发光散射检测器法测定参松养心胶囊中人参皂苷Rg1和Re含量

目的：建立测定参松养心胶囊中人参皂苷Rg1和Re含量的超高效液相色谱－蒸发光散射检测器（UPLC－ELSD）法。方法采用Waters ACQUITY UPLC BEH C18柱（100 mm ×2.1 mm,1.7μm）为色谱柱,以乙腈－水为流动相(梯度洗脱),流速为0.45 mL/min,柱温为35℃,进样量为2μL,ACQUITY ELSD检测器的漂移管温度为50℃,气体流量为30.0 psi。结果参松养心胶囊中人参皂苷Rg1和Re进样量分别在0.09108~1.1358μg和0.08306~1.03825μg范围内与峰面积线性关系良好,平均加样回收率分别为99.01%和99.25%,RSD分别为0.50%和0.36%（ n=6）。结论与高效液相色谱（HPLC）法相比,UPLC法在不影响分离效果的情况下大大提高了参松养心胶囊中人参皂苷Rg1和Re的分离速度,同时减少了溶剂消耗。UPLC法可作为替代传统HPLC法的一种更方便、快捷、可靠的方法。     

Uso de la cápsula endoscópica en enfermedad inflamatoria intestinal en práctica clínica en España. Resultados de una encuesta nacional

IntroductionSmall bowel capsule endoscopy (SBCE) is a non-invasive diagnostic technique whose use in inflammatory bowel disease (IBD) has spread. A panenteric capsule, PillCam Crohn's (PCC), has recently been developed. We lack information on the availability and use of the CEID and PCC in our environment.MethodsWe conducted an electronic and anonymous survey among the members of the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) [Spanish Working Group on Crohn's Disease and Ulcerative Colitis] and the Asociación Española de Gastroenterología (AEG) [Spanish Association of Gastroenterology], consisting of 37 multiple-choice questions.ResultsOne hundred and fifty members participated, the majority dedicated to IBD (69.3%). 72.8% worked at centres with an IBD unit. 79% had SBCE available at their hospital, 14% referred patients to another centre; 22% had a PCC available, 9% referred patients to another centre. 79.3% of respondents with available SBCE used it in a small percentage of patients with IBD and 15.6% in the majority. The most frequent scenarios were suspicion of Crohn's disease (76.3%), assessment of inflammatory activity (54.7%) and assessment of the extent of the disease (54.7%). More than half (59.7%) preferentially used the Patency capsule to assess intestinal patency. Almost all respondents (99.3%) considered that training resources should be implemented in this technique.ConclusionsSBCE is widely available in Spanish hospitals for the management of IBD, although its use is still limited. There is an opportunity to increase training in this technique, and consequently its use.     

Utilidad de la cápsula endoscópica en el diagnóstico de la enfermedad injerto contra huésped gastrointestinal

Introduction and aimGraft-versus-host disease (GvHD) is a complication of hematopoietic cell transplantation, and the small bowel is one of the main targets in the gastrointestinal tract. Capsule endoscopy is a safe procedure and can be useful in the diagnosis of GvHD. The aim of the present study was to compare the diagnostic yield of capsule endoscopy with the histopathologic findings in GvHD.Materials and methodsA retrospective diagnostic test study included all the patients with suspected GvHD that underwent gastroscopy and colonoscopy, with histopathologic evaluation of the biopsies taken, and capsule endoscopy, within the time frame of July 2015 and July 2019. Capsule endoscopy findings were compared with the histopathologic diagnosis, considered the gold standard.ResultsTwenty-one patients with GvHD (7 [33%] women; 37 ± 11.9 years of age) were included, 20 (95%) of whom had acute GvHD. The median gastric transit time of the capsule was 55 minutes (20-113) and the median small bowel transit time was 261 minutes (238-434). The entire small bowel was visualized through capsule endoscopy in 17 cases (80.95%). The histopathologic findings and capsule endoscopy findings resulted in the diagnosis of GvHD in 17 and 16 cases, respectively. There was agreement between the histopathologic and capsule endoscopy findings in 18 cases (15 positive and 3 negative). Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic yield of capsule endoscopy were 88%, 75%, 94%, 60%, and 85%, respectively.ConclusionsCapsule endoscopy is a safe tool for the diagnosis of GvHD, with high sensitivity and positive predictive value, as well as moderate agreement with histopathologic findings.     

红景天胶囊对兔急性心肌缺血再灌注损伤的保护作用

目的 研究红景天胶囊对兔急性心肌缺血再灌注损伤的的影响及其保护机制.方法 实验选取10只健康日本大耳白兔为假手术组,另取20只随机分为模型组及红景天组,2组均采用手术结扎左侧冠状动脉前降支30 min后再灌注60min,反复3次以造成急性心肌缺血再灌注损伤动物模型.术后3组动物均灌胃给药,测定治疗前及治疗1、2周总超氧化物歧化酶(T-SOD)、一氧化氮(NO)、血管内皮素-1(ET-1)、血清丙二醛(MDA)、血清肌酸激酶(CK)、白细胞介素-6(IL-6)水平,记算治疗2周后兔心肌缺血梗死率(％)等指标,并分析红景天胶囊对兔急性心肌缺血再灌注损伤的影响.结果 红景天胶囊明显提高红景天组兔NO含量及T-SOD活性,降低ET-1及血清MDA、CK、IL-6水平,减少急性心肌缺血梗死率,与模型组比较,差异均有统计学意义(P＜0.05).结论 红景天胶囊可提高兔急性心肌缺血再灌注后T-SOD及NO活性,促进氧自由基清除酶清除氧自由基、降低心肌缺血时脂质过氧化,进而改善再灌注损伤后受损血管内皮并维持其正常功能,增加心肌组织耐缺氧能力,对急性心肌缺血再灌注具有保护作用.     

银丹心脑通软胶囊对2型糖尿病氧化应激及血管内皮功能的影响

目的：研究银丹心脑通软胶囊对2型糖尿病氧化应激及血管内皮功能的影响。方法86例2型糖尿病患者按照随机数字表法分成常规降糖治疗组（常规组,n＝40）和银丹心脑通软胶囊治疗组（银丹心脑通组,n＝46）。常规组患者在控制饮食、运动等基础上给予降糖治疗使血糖连续达标12周,银丹心脑通组在常规治疗血糖达标基础上加用银丹心脑通软胶囊（每次1．2 g ,每日3次）连续治疗12周。检测两组患者治疗前后血脂、丙二醛（MDA）、超氧化物歧化酶（SOD）、一氧化氮（NO）、内皮素（ET）等相关因素变化,应用超声检测肱动脉血流介导的内皮依赖性舒张功能（FMD）和非内皮依赖性血管舒张功能（NMD）。结果治疗12周后两组患者血浆总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL‐C）、MDA、ET 较治疗前均有明显下降,高密度脂蛋白胆固醇（HDL‐C）、SOD、NO、FMD则较治疗前升高（P＜0．05）;而且银丹心脑通组治疗后上述各项指标与常规组治疗后比较也有显著变化（P＜0．05）。结论银丹心脑通软胶囊可下调2型糖尿病氧化应激,调节糖尿病脂代谢异常,明显改善损伤的血管内皮功能。     

降脂通络软胶囊联合瑞舒伐他汀对2型糖尿病合并高脂血症患者效果观察?

目的：观察降脂通络软胶囊联合瑞舒伐他汀治疗2型糖尿病合并高脂血症的临床疗效,并探讨其可能的机制。方法80例2型糖尿病合并高脂血症患者分为联合组与对照组(n=40)。在常规治疗基础上,联合组给予口服瑞舒伐他汀10 mg,1次/天,降脂通络软胶囊100 mg,3次/天口服,对照组予瑞舒伐他汀10 mg,1次/天,口服,连续用药12周。治疗前后分别检测肝功能、肾功能、肌酸激酶,各项血脂指标。结果治疗12周后,联合组在降低血清胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)及超敏 C-反应蛋白(hs-CRP)方面和升高高密度脂蛋白胆固醇(HDL-C)明显优于对照组,差异有统计学意义(P <0.05)。结论瑞舒伐他汀能有效治疗2型糖尿病高脂血症,联合降脂通络软胶囊应用疗效更佳,并且安全性良好。     

A Multicenter,Randomized,Double-blind Clinical Study on Wufuxinnaoqing Soft Capsule(五福心脑清胶囊) in Treatment of Chronic Stable Angina Patients with Blood Stasis Syndrome

Objective:To confirm the efficacy and safety of Wufuxinnaoqing Soft Capsule(五福心脑清胶囊,WSC)in the treatment of chronic stable angina(blood stasis syndrome).Methods:A multicenter,randomized,double-blind,placebo-controlled trial with superiority test was designed.A total of 240 patients with chronic stable angina(blood stasis syndrome)from multiple centers were randomly and equally assigned to the treatment group and the control group.Based on standard treatment of Westem medicine,the treatment group was given WSC,while the control group was given WSC mimetic,both for 12 weeks.Observed indicators included the efficacy in angina,the efficacy in Chinese medicine syndrome,the withdrawal or reduce rate of nitroglycerin and routine safety indices.Results:After 12-week treatment,the significant effective rate and total effective rate of the treatment group were significantly better than those of the control group(23.5%vs.9.2%,64.7%vs.30.8%),respectively,with statistically significant difference(P0.01).After 12-week treatment,the decreased points and the decreased rate of angina symptom score in the treatment group were better than in the control group(5.1±4.2 points vs.2.8±3.5 points,44.9%±37.2%vs.25.4%±30.7%)respectively,with significant difference(P0.01).After 12-week treatment,the significant effective rate and total effective rate of the treatment group were better than the control group(respectively,30.3%vs.15.0%,67.2%vs.45.0%,P0.01).After 8-or 12-week treatment,the decreased points and the decreased rate of Chinese medicine syndrome score in the treatment group were better than the control group(P0.05 or P0.01).After 12-week treatment,nitroglycerin withdrawal rate and the withdrawal or reduce rate in treatment group were better than the control group(P0.01).On safety evaluation,the incidence of adverse events(7.563%vs.7.500%)and the incidence of cardiovascular events(0.840%vs.0.000%)in the treatment group were similar with the control group,and the difference was not statistically significant(P0.05).Conclusion:In treatment of chronic stable angina(blood stasis syndrome),WSC can reduce angina attacks and consumption of nitroglycerin,decrease angina severity degree,effectively relieve the blood stasis syndromes,such as chest pain,chest tightness,palpitations,dark purple tongue and other symptoms.Besides,adverse events and cardiovascular adverse events in the treatment group and the control group showed no difference.All shows that the drug is safe and effective.[This study was registered in Chinese Clinical Trial Registry(ChiCTR),with registration number:ChiCTR-TRC-14005158.]